Rana McKay: Welcome, today. Thank you for joining us on UroToday. We have our wonderful guest Andrea Apolo giving us a recap of this year’s virtual ASCO meeting. Andrea is the head of the Bladder Section of the GU Malignancies Branch of the NCI and we are so excited to have her here with us […]
(UroToday.com) The 2021 American Society of Clinical Oncology annual meeting featured a session discussing optimizing urothelial cancer management from organ-confined to metastatic disease: A multidisciplinary approach. The chair/moderator for this session was Dr. Evan Yu from the University of Washington, Fred Hutchinson Cancer Research Center, the medical oncologist was Dr. Noah Hahn from Johns Hopkins University, […]
(UroToday.com) Testis cancer is the most common cancer in young men. Advanced testis cancer is one of the true success stories of modern oncology in which we can reasonably consider a cure for patients with advanced disease.
To investigate the safety and efficacy of OTL38, a folate-targeted, intraoperative fluorescence agent, in patients undergoing robotic-assisted laparoscopic partial nephrectomy. Patients with proven or suspected localized renal cell carcinoma at a single academic institution were selected from 2016 to 2018.
Primary tumour response may impact therapeutic strategies in metastatic renal cell carcinoma (mRCC) but remains unknown in the era of immune checkpoint inhibitors. We aimed to describe the response of the primary tumour in patients who did not undergo upfront cytoreductive nephrectomy (uCN) and were treated with nivolumab in the GETUG-AFU-26 NIVOREN phase 2 trial.
Long-term outcomes of prostate cancer (CaP) patients treated with radical prostatectomy (RP) from European cohorts are under-reported. We report on 22,843 RP patients from the Martini-Klinik Prostate Cancer Centre treated between 1992 and 2017.
The association between PSA density, prostate cancer (PCa) and BPH is well established. The aim of the present study was to establish whether PSA density can be used as a reliable parameter to predict csPCa and to determine its optimal cutoff to exclude increased PSA levels due to intraprostatic inflammation.
To characterize the oncologic outcomes five years following focal laser ablation (FLA) of localized prostate cancer. 36 men underwent in-bore FLA of prostate cancer at our institution between 2013 and 2015.
The objective of this study was to evaluate the impact of body mass index (BMI) on overall survival, freedom from distant metastases, rates of therapeutic intervention (TI), and quality of life (QOL) in active surveillance (AS) prostate cancer patients.
To examine overall survival rates within a large cohort of German prostate cancer (PCa) patients and to compare these with life-expectancy (LE) predictions derived from German life tables. We hypothesized that the advantage of good general health in radical prostatectomy (RP) patients combined with favorable cancer outcomes might lead to even higher overall survival rates […]
